预约演示
更新于：2025-09-18
Tagitanlimab
塔戈利单抗
更新于：2025-09-18
概要
基本信息
药物类型 单克隆抗体 |
别名 泰特利单抗、A 167、A-167 + [5] |
靶点 |
作用方式 抑制剂 |
作用机制 PDL1抑制剂(程序性死亡配体1抑制剂) |
在研适应症 |
非在研适应症 |
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2024-12-25), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 432479729L
来源: *****
Sequence Code 432479731H
来源: *****
关联
18
项与 塔戈利单抗 相关的临床试验NCT07179783
Phase II Study of the Combination of Sacituzumab Tirumotecan(SKB264)and Tagitanlimab (KL-A167) in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
NCT07153965
An Open-label, Single-arm, Multicenter Phase II Study of Sacituzumab Tirumotecan (Sac-TMT) Plus Tagitanlimab in Previously Treated PD-L1-positive Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
NCT07109284
A Single Arm, Multi-center Phase II Study of Neoadjuvant Therapy With Sacituzumab Tirumotecan (Sac-TMT) and KL-A167 for Early-stage, High-risk ER+/HER2- Breast Cancer (NeoSaciA)
100 项与 塔戈利单抗 相关的临床结果
登录后查看更多信息
100 项与 塔戈利单抗 相关的转化医学
登录后查看更多信息
100 项与 塔戈利单抗 相关的专利（医药）
登录后查看更多信息
7
项与 塔戈利单抗 相关的文献（医药）2019-06-01Plant disease2区 · 农林科学
Compatible Mixture of Bacterial Antagonists Developed to Protect Potato Tubers from Soft Rot Caused by Pectobacterium spp. and Dickeya spp.
2区 · 农林科学
Article
作者: Krychowiak, Marta ; Czajkowski, Robert ; Krzyzanowska, Dorota M. ; Maciag, Tomasz ; Siwinska, Joanna ; Jafra, Sylwia
Possibilities to protect potato tubers from rotting caused by Soft Rot Pectobacteriaceae (SRP) under disease favoring conditions were investigated using compatible mixtures of bacterial antagonists and tested with a newly developed stepwise efficacy-based screening protocol. Twenty-two bacterial antagonists were evaluated against a combination of five Pectobacterium and Dickeya strains representing species and subspecies most often associated with potato soft rot in Europe. To enable potential synergistic activity, the antagonists were initially tested against the combination of pathogens in 15 random mixtures containing up to 5 antagonists each. Three mixtures (M2, M4, and M14) out of 15 tested reduced tuber tissue maceration due to soft rot. The individual antagonists derived from M2, M4, and M14 mixtures were tested on potato slices and whole tuber injection assays. These five strains (S. plymuthica strain A294, E. amnigenus strain A167, R. aquatilis strain H145, S. rubidaea strain H440, and S. rubidaea strain H469) were combined to develop a tailored biological control mixture against potato soft rot. The new mixture, designated the Great Five (GF), was tested on seed potato tubers vacuum infiltrated with antagonists and subsequently with the combination of five SRP pathogens. In these experiments, the GF mixture provided stable protection of inoculated potato tubers, reducing soft rot by 46% (P = 0.0016) under high disease pressure conditions. The A294, A167, H145, H440, and H469 antagonists were characterized for features important for viable commercial applications including growth at different temperatures, resistance to antibiotics, and potential toxicity toward Caenorhabditis elegans. The implications for control of soft rot caused by SRP with the use of the GF mixture of antagonists are discussed.
2014-11-01Bioorganic & medicinal chemistry letters4区 · 医学
From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: Synthesis and biological evaluation of valproic esters of 3′-C-methyladenosine
4区 · 医学
Article
作者: Hofer, Anders ; Vodnala, Munender ; Meli, Maria ; Torquati, Ilaria ; Vita, Patrizia ; D'Alessandro, Natale ; Ferro, Arianna ; Grifantini, Mario ; Franchetti, Palmarisa ; Tolomeo, Manlio ; Jayaram, Hiremagalur N ; Kusumanchi, Praveen ; Petrelli, Riccardo ; Del Bello, Fabio ; Cappellacci, Loredana
We synthesized a series of serum-stable covalently linked drugs derived from 3'-C-methyladenosine (3'-Me-Ado) and valproic acid (VPA), which are ribonucleotide reductase (RR) and histone deacetylase (HDAC) inhibitors, respectively. While the combination of free VPA and 3'-Me-Ado resulted in a clear synergistic apoptotic effect, the conjugates had lost their HDAC inhibitory effect as well as the corresponding apoptotic activity. Two of the analogs, 2',5'-bis-O-valproyl-3'-C-methyladenosine (A160) and 5'-O-valproyl-3'-C-methyladenosine (A167), showed promising cytotoxic activities against human hematological and solid cancer cell lines. A167 was less potent than A160 but had interesting features as an RR inhibitor. It inhibited RR activity by competing with ATP as an allosteric effector and concomitantly reduced the intracellular deoxyribonucleoside triphosphate (dNTP) pools. A167 represents a novel lead compound, which in contrast to previously used RR nucleoside analogs does not require intracellular kinases for its activity and therefore holds promise against drug resistant tumors with downregulated nucleoside kinases.
1993-01-01Biological & pharmaceutical bulletin4区 · 医学
Mitogenic Activity and Lethal Toxicity of Lipid A Analogs, Glucosamine-phosphate Carrying Aromatic Alkyl Groups, in Mice.
4区 · 医学
Article
作者: Yanagihara, Yasutake ; Iwamoto, Yoshihisa ; Nakamoto, Shinichi ; Achiwa, Kazuo ; Shimizu, Tadayori ; Itoh, Hajime
The mitogenicity and lethal toxicity of four synthetic lipid A analogs, glucosamine-4-phosphate with a 7-hydroxy-heptanoyl group (A-166), with a 7-phenyl-heptanoyl group (A-167), or with a 8-(1-phenyl-hexanoyl)-nonanoyl group (A-168), at the C-2 and C-3 positions, and glucosamine-6-phosphate with the same substituents as A-168 at C-2 and C-3 (A-169), were compared. The compound A-166 exhibited no mitogenic activity at various concentrations ranging from 3.13 to 50 micrograms/ml in the splenocytes of BALB/c mice, but A-167 exhibited weak mitogenic activity at concentrations of 12.5 and 25 micrograms/ml. A-168 and A-169, as well as A-103, glucosamine-4-phosphate carrying (R)-3-tetradecanoyl-oxytetradecanoyl groups, have remarkable mitogenic activity at concentrations ranging from 12.5 to 100 micrograms/ml; the activity of A-169 (6-phosphate) was stronger than that of A-168 (4-phosphate). Compound A-167 failed to cause death at doses of 25 and 50 micrograms/mouse in galactosamine-loaded C57BL/6 mice while A-166 and A-169 were toxic to 2 out of 6 mice at 50 micrograms/mouse; no deaths were observed at 25 micrograms/mouse. A-168 showed the highest toxicity of any of the compounds tested at 25 and 50 micrograms/mouse. The lethal effect of A-103 appeared to be somewhere between that of A-168 and A-169. These findings indicate that lipid A analogs, carrying an aromatic alkyl group as well as a hydroxyacyl group, are mitogenic and lethal when given to mice.
229
项与 塔戈利单抗 相关的新闻（医药）2025-09-14
·信狐药迅
2025-09-04
突破性疗法抗体药物偶联物免疫疗法临床申请
2025-08-28
优先审批突破性疗法临床3期抗体药物偶联物免疫疗法
100 项与 塔戈利单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼻咽癌 | 中国 | 2024-12-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性去势抵抗性前列腺癌 | 临床2期 | 中国 | 2025-09-22 | |
| 前列腺腺癌伴神经内分泌分化 | 临床2期 | 中国 | 2025-09-22 | |
| 遗传性前列腺癌7型 | 临床2期 | 中国 | 2025-09-22 | |
| 神经内分泌前列腺癌 | 临床2期 | 中国 | 2025-09-22 | |
| HER2 阴性乳腺癌 | 临床2期 | 中国 | 2022-08-17 | |
| 难治性经典霍奇金淋巴瘤 | 临床2期 | 中国 | 2018-07-17 | |
| 复发性经典霍奇金淋巴瘤 | 临床2期 | 中国 | 2018-07-17 | |
| 弥漫性大B细胞淋巴瘤 | 临床1期 | 中国 | 2018-09-19 | |
| 结外NK-T细胞淋巴瘤 | 临床1期 | 中国 | 2018-09-19 | |
| 晚期恶性实体瘤 | 临床1期 | 中国 | 2017-12-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 晚期非小细胞肺癌 一线 | 103 | (Cohort 1A) | 憲網鹹製網鏇艱選築襯(襯觸淵顧鑰構憲鬱糧廠) = 糧願築鏇願醖觸範簾製 蓋顧憲選築壓齋網壓構 (窪網鏇鏇鏇襯範衊醖窪 ) 更多 | 积极 | 2025-08-19 | |
(Cohort 1B) | 憲網鹹製網鏇艱選築襯(襯觸淵顧鑰構憲鬱糧廠) = 壓齋鏇網網衊積膚蓋夢 蓋顧憲選築壓齋網壓構 (窪網鏇鏇鏇襯範衊醖窪 ) 更多 | ||||||
临床2期 | 晚期非小细胞肺癌 一线 | 103 | 範餘積觸廠憲淵窪鬱淵(獵蓋築積醖構鹹醖廠窪) = 蓋鬱廠淵餘願齋艱衊廠 衊鑰餘蓋鑰簾觸夢蓋鑰 (遞膚糧積鏇襯艱製廠蓋 ) 更多 | 积极 | 2025-08-19 | ||
Sacituzumab tirumotecan 5 mg kg-1 every 2 weeks + Tagitanlimab 900 mg every 2 weeks | 範餘積觸廠憲淵窪鬱淵(獵蓋築積醖構鹹醖廠窪) = 願網壓糧窪憲簾簾簾觸 衊鑰餘蓋鑰簾觸夢蓋鑰 (遞膚糧積鏇襯艱製廠蓋 ) 更多 | ||||||
临床2期 | 晚期非小细胞肺癌 一线 | 81 | 積襯積憲簾繭鏇糧鑰觸(願齋餘製廠醖範蓋壓鹽) = 選壓鹽繭襯積遞衊壓壓 鑰繭餘網選選醖製壓網 (膚膚觸蓋構積窪廠積衊 ) 更多 | 积极 | 2025-05-30 | ||
临床3期 | 295 | 製遞壓壓衊襯觸窪願憲(襯獵選艱鹽顧衊憲鑰襯) = 艱願鹽淵鏇夢鏇夢廠鏇 製築糧積鹽窪鬱鬱築網 (齋顧獵齋壓簾鹹鏇壓繭, 10.9 ~ NE) 更多 | 积极 | 2025-05-30 | |||
製遞壓壓衊襯觸窪願憲(襯獵選艱鹽顧衊憲鑰襯) = 艱齋餘簾築膚顧鑰憲積 製築糧積鹽窪鬱鬱築網 (齋顧獵齋壓簾鹹鏇壓繭, 6.9 ~ 8.3) 更多 | |||||||
临床3期 | - | 塔戈利单抗+顺铂+吉西他滨 | 窪憲觸壓願願蓋鹽構鹽(餘願糧築糧艱艱鏇範選) = 齋廠築壓顧鑰製憲衊蓋 壓構網築遞網夢鹽繭觸 (窪顧觸鏇襯鏇餘選醖築 ) 更多 | 积极 | 2025-01-21 | ||
安慰剂+顺铂+吉西他滨 | 窪憲觸壓願願蓋鹽構鹽(餘願糧築糧艱艱鏇範選) = 鬱遞積餘顧築範壓壓醖 壓構網築遞網夢鹽繭觸 (窪顧觸鏇襯鏇餘選醖築 ) 更多 | ||||||
临床2期 | 非小细胞肺癌 一线 | 103 | 顧醖淵範觸顧構鏇簾夢(繭衊構鏇獵窪憲衊夢襯) = 廠觸繭鹽願願遞繭鏇淵 繭艱餘衊醖築餘繭窪繭 (遞壓廠鹽範簾齋憲鬱製 ) 更多 | 积极 | 2024-05-24 | ||
顧醖淵範觸顧構鏇簾夢(繭衊構鏇獵窪憲衊夢襯) = 繭願選構壓觸憲構醖繭 繭艱餘衊醖築餘繭窪繭 (遞壓廠鹽範簾齋憲鬱製 ) 更多 | |||||||
临床2期 | 153 | KL-A167 900mg | 鬱襯夢遞糧遞網蓋夢製(艱齋遞蓋鹹積憲膚膚鑰) = 窪觸夢艱製鑰鹹壓鏇醖 繭壓衊廠衊糧襯觸衊鏇 (餘淵選構鹽糧鏇觸蓋夢, 19.2 ~ 34.9) 更多 | 积极 | 2022-10-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用